Evidence map›Paper›PMID 30132036›Full record

ReviewDiabetologia2018

SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.

Subodh Verma, John J V McMurray

5 registry-linked trialsOpen access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Diabetologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT05194592. Cited by 479 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
479citing papers in PubMed, 12 pooled it
66.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05194592 phase4unknown statusstarted 2022, after this paper: background citation

Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes

Ran2022Enrolled122Registered outcomes4Posted comparisons0ConditionsRemodeling, Ventricular, Type2 DiabetesArmsdapagliflozin, Gemigliptin
PMID 32943171PMID 33648515PMID 32578850PMID 32358544PMID 25271206other papers from this trial
Open the trial in the graph
NCT07379788 nacompletedstarted 2025, after this paper: background citation

Mitral Remodeling Index: A Novel Composite Measure the Effect of ARNI Alone Versus ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling.

Ran2025Enrolled180Registered outcomes4Posted comparisons0ConditionsHeart FailureArmsEmpagliflozin10Mg Tab, Sacubitril/Valsartan 49 MG-51 MG Oral Tablet [ENTRESTO]
PMID 25176015other papers from this trial
Open the trial in the graph
NCT07465926 completed

Associations of Early Add-On GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy With Mortality and Kidney Outcomes in Adults With Obesity and Type 2 Diabetes Across Cardiovascular-Kidney-Metabolic Stages 2-3: A Target-Trial Emulation

Ran2017Enrolled451,036Registered outcomes12Posted comparisons0ConditionsCardiovascular Disease Risk Factor, Cardiovascular-kidney-metabolic Syndrome, Kidney Disease, Obesity & OverweightArmsGLP-1 receptor agonist, SGLT2 inhibitor
PMID 32114848PMID 38785209PMID 40281304PMID 27295427PMID 39342059PMID 39556396PMID 39588897PMID 39651970PMID 39651975PMID 39961105PMID 39992643PMID 40014670other papers from this trial
Open the trial in the graph
NCT04780438 early_phase1unknown statusnot on this mapstarted 2021, after this paper: background citation

Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation.

TypeinterventionalSponsorG.Gennimatas General HospitalRan2021 to 2023Enrolled350ConditionsAtrial Fibrillation Recurrent, Pulmonary Venous Isolation, Catheter Ablation, Sodium-glucose Co-transporter 2 InhibitorsArmsDapagliflozin, Placebo
NCT06326528 unknown statusnot on this mapstarted 2024, after this paper: background citation

Short Term Outcome of SGLT2 Inhibitors on Patients Who Undergo Cardiac Surgery in Perioperative Period

TypeobservationalSponsorAssiut UniversityRan2024 to 2025Enrolled100ConditionsPerioperative ComplicationArmsSGLT2 inhibitor
3 · Its place in the literature

Who cites it

479 citing papers in PubMed, 12 syntheses or guidelines pooled it, 925 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

419 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Subodh VermaDivision of Cardiac Surgery, Li Ka Shing Knowledge Institute of St Michael's Hospital, University of Toronto, 30 Bond Street, Toronto, ON, M5B 1W8, Canada. vermasu@smh.ca.
John J V McMurrayBritish Heart Foundation, Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
St. Michael's Hospital · CAUniversity of Glasgow · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sodium-glucose cotransporter (SGLT)2 inhibitors have been demonstrated to reduce cardiovascular events, particularly heart failure, in cardiovascular outcome trials. Here, we review the proposed mechanistic underpinnings of this benefit. Specifically, we focus on the role of SGLT2 inhibitors in optimising ventricular loading conditions through their effect on diuresis and natriuresis, in addition to reducing afterload and improving vascular structure and function. Further insights into the role of SGLT2 inhibition in myocardial metabolism and substrate utilisation are outlined. Finally, we discuss two emerging themes: how SGLT2 inhibitors may regulate Na

Indexed as

AdipokinesAnimalsBenzhydryl CompoundsBlood GlucoseCardiovascular DiseasesDiabetes ComplicationsDiabetes Mellitus, Type 2GlucosidesHeartHeart VentriclesHumansHypoglycemic AgentsKidneySodium-Glucose Transporter 2 InhibitorsAdipokinesBenzhydryl CompoundsBlood GlucoseGlucosidesHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsCardiovascular effectsHeart failureMechanismsReviewSGLT2 inhibitors

Identifiers

PMID30132036
OpenAlexW2884466498

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.